Please contact us for more information or to learn if you are eligible to participate.
This phase III trial compares immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma.
Dr. Jose Cruz
Edgar Lopez Pacheco
National Cancer Institute (NCI)
Type of Trial